Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
 combination product on 25 May 2016 - EconoTimes)
- The briefing documents posted on FDA's website include results from the two Phase III trials with the lixisenatide/Lantus(r) combination, not previously published
- US regulatory decisions on lixisenatide and the lixisenatide/Lantus(r) combination are expected in July and August 2016, respectively
COPENHAGEN, Denmark, May 23, 2016 -- Zealand announces that the US Food and Drug Administration (FDA) today has made briefing documents on lixisenatide and the lixisenatide/Lantus(r) combination available on its website. The documents relate to the upcoming meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, scheduled by the FDA for 8:00 am to 5:00 pm ET on 25 May 2016 to discuss the New Drug Applications (NDAs) for the two drug products intended for the treatment of adults with Type 2 diabetes. The NDAs were submitted by Sanofi.
The briefing documents contain the key points for discussion at the Advisory Committee meeting and background information on lixisenatide and the lixisenatide/Lantus(r) combination. This include the results from Sanofi's two clinical Phase III trials with the lixisenatide/Lantus(r) combination, LixiLan-L and LixiLan-O, which have not previously been published. The briefing documents can be accessed under the following link: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm491062.htm
Lixisenatide is a once-daily GLP-1 receptor agonist, invented by Zealand and with global development and commercial rights licensed to Sanofi. The lixisenatide/Lantus(r) combination is a fixed-ratio combination of lixisenatide and basal insulin glargine (100 U/mL), developed by Sanofi under the license agreement with Zealand.
Sanofi submitted the US NDA on lixisenatide in July 2015 and it was accepted by the FDA for regulatory review in September 2015. A regulatory decision on lixisenatide is expected in July 2016. In December 2015, Sanofi submitted the US NDA on the lixisenatide/Lantus(r) combination product, redeeming a Priority Review Voucher with the submission. In February the FDA accepted the NDA for priority review with a regulatory decision expected in August 2016.
